Skip to main content

Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions.

Publication ,  Journal Article
Morishita, K; Guzman, J; Chira, P; Muscal, E; Zeft, A; Klein-Gitelman, M; Uribe, AG; Abramson, L; Benseler, SM; Eberhard, A; Ede, K; Hersh, AO ...
Published in: J Rheumatol
October 2012

OBJECTIVE: To determine whether adult disease severity subclassification systems for antineutrophil cytoplasmic antibody-associated vasculitis (AAV) are concordant with the decision to treat pediatric patients with cyclophosphamide (CYC). METHODS: We applied the European Vasculitis Study (EUVAS) and Wegener's Granulomatosis Etanercept Trial (WGET) disease severity subclassification systems to pediatric patients with AAV in A Registry for Childhood Vasculitis (ARChiVe). Modifications were made to the EUVAS and WGET systems to enable their application to this cohort of children. Treatment was categorized into 2 groups, "cyclophosphamide" and "no cyclophosphamide." Pearson's chi-square and Kendall's rank correlation coefficient statistical analyses were used to determine the relationship between disease severity subgroup and treatment at the time of diagnosis. RESULTS: In total, 125 children with AAV were studied. Severity subgroup was associated with treatment group in both the EUVAS (chi-square 45.14, p < 0.001, Kendall's tau-b 0.601, p < 0.001) and WGET (chi-square 59.33, p < 0.001, Kendall's tau-b 0.689, p < 0.001) systems; however, 7 children classified by both systems as having less severe disease received CYC, and 6 children classified as having severe disease by both systems did not receive CYC. CONCLUSION: In this pediatric AAV cohort, the EUVAS and WGET adult severity subclassification systems had strong correlation with physician choice of treatment. However, a proportion of patients received treatment that was not concordant with their assigned severity subclass.

Duke Scholars

Published In

J Rheumatol

DOI

EISSN

1499-2752

Publication Date

October 2012

Volume

39

Issue

10

Start / End Page

2012 / 2020

Location

Canada

Related Subject Headings

  • Severity of Illness Index
  • Practice Patterns, Physicians'
  • Male
  • Immunosuppressive Agents
  • Humans
  • Female
  • Cyclophosphamide
  • Child, Preschool
  • Child
  • Arthritis & Rheumatology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Morishita, K., Guzman, J., Chira, P., Muscal, E., Zeft, A., Klein-Gitelman, M., … ARChiVe Investigators Network. (2012). Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions. J Rheumatol, 39(10), 2012–2020. https://doi.org/10.3899/jrheum.120299

Published In

J Rheumatol

DOI

EISSN

1499-2752

Publication Date

October 2012

Volume

39

Issue

10

Start / End Page

2012 / 2020

Location

Canada

Related Subject Headings

  • Severity of Illness Index
  • Practice Patterns, Physicians'
  • Male
  • Immunosuppressive Agents
  • Humans
  • Female
  • Cyclophosphamide
  • Child, Preschool
  • Child
  • Arthritis & Rheumatology